Abstract
Prostate cancer constitutes a major health care dilemma in terms of treatment options available and increasing patient load on both a regional and national level. An audit was undertaken of all patients in the South West Region with localised prostate cancer newly diagnosed in 1993 to assess regional management of this disease. In 1993, 1407 patients were newly diagnosed as having prostatic cancer. Patients > 75 years old and those with a prostate-specific antigen (PSA) > 40 ng/ml were excluded, leaving 262 patients whose case notes were examined. The interval between referral and clinic (mean 67 days) was altered by the presence of a GP performed PSA, being shorter if the PSA was > 10 ng/ml (average 54 days) than if the PSA was < 10 ng/ml (average 104 days). Overall, 34% of patients underwent radical treatment (10% radical prostatectomy and 24% radiotherapy). In all, 27% received hormone manipulation or orchidectomy, and the remainder 'watchful waiting'. The majority (78%) of patients < 60 years old received radical treatment, as did 35% of those 60-70 years and 15% of 70-75 year olds. Over 90% of tumours were category T1 and were well or moderately differentiated. All patients had a histological diagnosis and 84% had their tumour staged before treatment. This study highlighted the need for improvements in patient assessment, improved note keeping and a regional cancer register to allow ongoing assessment of patient management. This audit of management of localised prostate cancer serves as a baseline from which to initiate and monitor improvements in the service regionally and will also allow assessment of the impact of such changes.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Adolfsson J., Steineck G., Whitmore W. F., Jr Recent results of management of palpable clinically localized prostate cancer. Cancer. 1993 Jul 15;72(2):310–322. doi: 10.1002/1097-0142(19930715)72:2<310::aid-cncr2820720203>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
- Badalament R. A., Miller M. C., Peller P. A., Young D. C., Bahn D. K., Kochie P., O'Dowd G. J., Veltri R. W. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol. 1996 Oct;156(4):1375–1380. [PubMed] [Google Scholar]
- Dearnaley D. P. Cancer of the prostate. BMJ. 1994 Mar 19;308(6931):780–784. doi: 10.1136/bmj.308.6931.780. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dorr V. J., Williamson S. K., Stephens R. L. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med. 1993 Nov 22;153(22):2529–2537. [PubMed] [Google Scholar]
- Fleming C., Wasson J. H., Albertsen P. C., Barry M. J., Wennberg J. E. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team. JAMA. 1993 May 26;269(20):2650–2658. [PubMed] [Google Scholar]
- Garraway W. M., Alexander F. E. Prostate disease: epidemiology, natural history and demographic shifts. Br J Urol. 1997 Apr;79 (Suppl 2):3–8. doi: 10.1111/j.1464-410x.1997.tb16915.x. [DOI] [PubMed] [Google Scholar]
- Gibbons R. P. Localized prostate carcinoma. Surgical management. Cancer. 1993 Nov 15;72(10):2865–2812. doi: 10.1002/1097-0142(19931115)72:10<2865::aid-cncr2820721002>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
- Hall R. R. Radical prostatectomy and prostate cancer screening: the need for national audit and research. Ann R Coll Surg Engl. 1994 Nov;76(6):367–372. [PMC free article] [PubMed] [Google Scholar]
- Heman-Ackah C. A., Festenstein J. B., Hibbert P., Harvey D. J., Bunce C. J., Gelister J. S. Experience with an assay for prostate-specific antigen and transrectal ultrasonography in the diagnosis of prostate cancer. Br J Urol. 1997 Mar;79(3):439–444. doi: 10.1046/j.1464-410x.1997.06723.x. [DOI] [PubMed] [Google Scholar]
- Johansson J. E., Adami H. O., Andersson S. O., Bergström R., Holmberg L., Krusemo U. B. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992 Apr 22;267(16):2191–2196. [PubMed] [Google Scholar]
- Krahn M. D., Mahoney J. E., Eckman M. H., Trachtenberg J., Pauker S. G., Detsky A. S. Screening for prostate cancer. A decision analytic view. JAMA. 1994 Sep 14;272(10):773–780. [PubMed] [Google Scholar]
- Kramer B. S., Brown M. L., Prorok P. C., Potosky A. L., Gohagan J. K. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993 Nov 1;119(9):914–923. doi: 10.7326/0003-4819-119-9-199311010-00009. [DOI] [PubMed] [Google Scholar]
- O'Dowd G. J., Veltri R. W., Orozco R., Miller M. C., Oesterling J. E. Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol. 1997 Sep;158(3 Pt 1):687–698. doi: 10.1097/00005392-199709000-00003. [DOI] [PubMed] [Google Scholar]
- Partin A. W., Oesterling J. E. The clinical usefulness of prostate specific antigen: update 1994. J Urol. 1994 Nov;152(5 Pt 1):1358–1368. doi: 10.1016/s0022-5347(17)32422-9. [DOI] [PubMed] [Google Scholar]
- Soloway M. S. Combined androgen blockade: an optimal therapy for minimally advanced prostate cancer? Br J Urol. 1998 Jan;81(1):87–95. doi: 10.1046/j.1464-410x.1998.00502.x. [DOI] [PubMed] [Google Scholar]
- Stamey T. A. Diagnosis of prostate cancer: a personal view. J Urol. 1992 Mar;147(3 Pt 2):830–832. doi: 10.1016/s0022-5347(17)37398-6. [DOI] [PubMed] [Google Scholar]
- Whitmore W. F., Jr, Warner J. A., Thompson I. M., Jr Expectant management of localized prostatic cancer. Cancer. 1991 Feb 15;67(4):1091–1096. doi: 10.1002/1097-0142(19910215)67:4<1091::aid-cncr2820670437>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]